Literature DB >> 23084853

Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight.

Stephen Wilson1, Leen Van Brussel, Gillian Saunders, Lucas Taylor, Lisa Zimmermann, Karl Heinritzi, Mathias Ritzmann, Elisabeth Banholzer, Matthias Eddicks.   

Abstract

The field efficacy and safety of a single-dose inactivated Mycoplasma hyopneumoniae vaccine, Suvaxyn MH-One, was evaluated in 4-5-day-old piglets on a commercial farm with a history of Mycoplasma disease in Southern Germany. The piglets were injected intramuscularly with the vaccine or saline (control group) and raised under commercial conditions to slaughter weight. The efficacy of the vaccine was determined by comparing the lung lesions associated with infection by M. hyopneumoniae in control and vaccinated pigs post mortem. In this analysis the vaccinated pigs had the lower mean percentage lung lesion at 5% compared to 9% in controls. Of the vaccinated pigs 52.3% were shown to have low levels of lung lesions between 0% and 5% and no more than 5.4% were shown to have levels above 20%. In contrast, the pigs administered saline showed 36.5% in the lower category (0-5%), while 18.3% showed lesions greater than 20%. There were significant differences in the mean body weight of pigs at the final two weight measurements at approximately 21 weeks and 26 weeks of age, with those receiving Suvaxyn MH-One being on average 5 kg heavier at each time point. There was also a significant increase in average daily gain in the vaccinated animals compared to the control group, particularly in the period from vaccination to the final two body weight measurements on day 138 and 166, from weaning at day 28 to the final two body measurements and from mid-way during finishing at day 84 to the final two body weight measurements. Vaccination had no adverse impact on appetite, although small numbers of vaccinated and control pigs did show mild signs of coughing, sneezing, respiratory distress or depression. There was no adverse impact on rectal temperatures and no signs of injection site reactions during the course of the study. We can conclude that vaccination with Suvaxyn MH-One to pigs at less than 1 week of age is effective in reducing lung lesions resulting from M. hyopneumoniae and also aids growth performance by reducing weight losses and improving average daily gain.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084853     DOI: 10.1016/j.vaccine.2012.10.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Experimental evaluation of Mycoplasma hyopneumoniae bacterin against a Korean M. hyopneumoniae challenge.

Authors:  SooHwan Kim; Taehwan Oh; Siyeon Yang; Hyejean Cho; Chanhee Chae
Journal:  Can J Vet Res       Date:  2021-01       Impact factor: 1.310

2.  Vaccination of piglets up to 1 week of age with a single-dose Mycoplasma hyopneumoniae vaccine induces protective immunity within 2 weeks against virulent challenge in the presence of maternally derived antibodies.

Authors:  Stephen Wilson; Leen Van Brussel; Gillian Saunders; Paul Runnels; Lucas Taylor; Dan Fredrickson; Jeremy Salt
Journal:  Clin Vaccine Immunol       Date:  2013-03-13

3.  Dynamics of Mycoplasma hyopneumoniae seroconversion and infection in pigs in the three main production systems.

Authors:  Enrico Giacomini; Nicola Ferrari; Alessandra Pitozzi; Michela Remistani; Daniele Giardiello; Dominiek Maes; Giovanni Loris Alborali
Journal:  Vet Res Commun       Date:  2016-05-04       Impact factor: 2.459

4.  Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae monovalent and bivalent vaccines against a dual challenge.

Authors:  Siyeon Yang; Su-Jin Park; Taehwan Oh; Hyejean Cho; Chanhee Chae
Journal:  Can J Vet Res       Date:  2020-10       Impact factor: 1.310

5.  A field efficacy trial of a trivalent vaccine containing porcine circovirus type 2a and 2b, and Mycoplasma hyopneumoniae in three herds.

Authors:  Hyungmin Um; Siyeon Yang; Taehwan Oh; Hyejean Cho; Kee Hwan Park; Jeongmin Suh; Chanhee Chae
Journal:  Vet Med Sci       Date:  2021-10-22

6.  The Effect of Inactivated Mycobacterium Paratuberculosis Vaccine on the Response to a Heterologous Bacterial Challenge in Pigs.

Authors:  Kristoffer Jarlov Jensen; Mette Sif Hansen; Peter Mikael Helweg Heegaard; Christine Stabell Benn; Gregers Jungersen
Journal:  Front Immunol       Date:  2019-07-05       Impact factor: 7.561

7.  Comparative Evaluation of Growth Performance between Bivalent and Trivalent Vaccines Containing Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae in a Herd with Subclinical PCV2d Infection and Enzootic Pneumonia.

Authors:  Hyungmin Um; Siyeon Yang; Taehwan Oh; Keehwan Park; Hyejean Cho; Jeongmin Suh; Kyung-Duk Min; Chanhee Chae
Journal:  Vaccines (Basel)       Date:  2021-05-03

8.  A field evaluation of two vaccines against Mycoplasma hyopneumoniae infection in pigs.

Authors:  Charlotte S Kristensen; Jens Vinther; Birgitta Svensmark; Poul Bækbo
Journal:  Acta Vet Scand       Date:  2014-04-16       Impact factor: 1.695

9.  Efficacy of Mycoplasma hyopneumoniae vaccination before and at weaning against experimental challenge infection in pigs.

Authors:  Ioannis Arsenakis; Luca Panzavolta; Annelies Michiels; Rubén Del Pozo Sacristán; Filip Boyen; Freddy Haesebrouck; Dominiek Maes
Journal:  BMC Vet Res       Date:  2016-03-29       Impact factor: 2.741

10.  Optimal vaccination strategy against Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus, and porcine circovirus type 2 in case of early M. hyopneumoniae infection.

Authors:  Siyeon Yang; Taehwan Oh; Josuke Mago; Akihiro Iwakuma; Chanhee Chae
Journal:  Vet Med Sci       Date:  2020-05-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.